A Pilot Study Evaluating the Efficacy of Regulatory T-Cell (T-Reg) Suppression by Denileukin Diftitox (Ontak) in Metastatic Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 08 Mar 2011 Planned end date changed from 1 Jun 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 23 Oct 2008 Actual start date (Oct 2008) added as reported by ClinicalTrials.gov.